221 related articles for article (PubMed ID: 33961012)
1. Dasatinib inhibits proliferation of liver cancer cells, but activation of Akt/mTOR compromises dasatinib as a cancer drug.
Liu C; Zhu X; Jia Y; Chi F; Qin K; Pei J; Zhang C; Mu X; Zhang H; Dong X; Xu J; Yu B
Acta Biochim Biophys Sin (Shanghai); 2021 Jul; 53(7):823-836. PubMed ID: 33961012
[TBL] [Abstract][Full Text] [Related]
2. Ponatinib Inhibits Proliferation and Induces Apoptosis of Liver Cancer Cells, but Its Efficacy Is Compromised by Its Activation on PDK1/Akt/mTOR Signaling.
Liu C; Mu X; Wang X; Zhang C; Zhang L; Yu B; Sun G
Molecules; 2019 Apr; 24(7):. PubMed ID: 30959969
[TBL] [Abstract][Full Text] [Related]
3. [Ponatinib inhibits the proliferation of SNU-449 human hepatocellular cancer cells and blocks MAPK and PDK1/AKT/mTOR signaling pathways].
Liu C; Pei J; Mu X; Yu B; Gong T; Liang W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 May; 38(5):425-431. PubMed ID: 35603651
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer.
Haga Y; Higashisaka K; Yang L; Sekine N; Lin Y; Tsujino H; Nagano K; Tsutsumi Y
Biochem Biophys Res Commun; 2020 Dec; 533(4):672-678. PubMed ID: 33036754
[TBL] [Abstract][Full Text] [Related]
5. Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway.
Wang B; Song K; Chen L; Su H; Gao L; Liu J; Huang A
Cell Biochem Funct; 2020 Jul; 38(5):642-650. PubMed ID: 32162707
[TBL] [Abstract][Full Text] [Related]
6. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Charette N; De Saeger C; Lannoy V; Horsmans Y; Leclercq I; Stärkel P
Mol Cancer; 2010 Sep; 9():256. PubMed ID: 20860815
[TBL] [Abstract][Full Text] [Related]
7. CXCL14 inhibits the growth and promotes apoptosis of hepatocellular carcinoma cells via suppressing Akt/mTOR pathway.
Bi J; Liu Q; Sun Y; Hu X; He X; Xu C
J Recept Signal Transduct Res; 2021 Dec; 41(6):593-603. PubMed ID: 33108937
[TBL] [Abstract][Full Text] [Related]
8. Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression.
Yori JL; Lozada KL; Seachrist DD; Mosley JD; Abdul-Karim FW; Booth CN; Flask CA; Keri RA
Cancer Res; 2014 Sep; 74(17):4762-71. PubMed ID: 25023728
[TBL] [Abstract][Full Text] [Related]
9. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.
Liu J; Zhang Y; Liu A; Wang J; Li L; Chen X; Gao X; Xue Y; Zhang X; Liu Y
Int J Mol Sci; 2016 Apr; 17(4):531. PubMed ID: 27070592
[TBL] [Abstract][Full Text] [Related]
10. Luteolin induces caspase-dependent apoptosis via inhibiting the AKT/osteopontin pathway in human hepatocellular carcinoma SK-Hep-1 cells.
Im E; Yeo C; Lee EO
Life Sci; 2018 Sep; 209():259-266. PubMed ID: 30107166
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.
Chen B; Xu X; Luo J; Wang H; Zhou S
PLoS One; 2015; 10(6):e0129663. PubMed ID: 26061184
[TBL] [Abstract][Full Text] [Related]
12. Local Anesthetic Drug Inhibits Growth and Survival in Chronic Myeloid Leukemia Through Suppressing PI3K/Akt/mTOR.
Zheng Q; Peng X; Yu H
Am J Med Sci; 2018 Mar; 355(3):266-273. PubMed ID: 29549929
[TBL] [Abstract][Full Text] [Related]
13. [Inhibitory effect and molecular mechanism of sinomenine on human hepatocellular carcinoma HepG2 and SK-HEP-1 cells].
Tian YY; Ma BB; Zhao XY; Liu C; Li YL; Yu SY; Tian SQ; Pei HL; Lyu YN; Zuo ZP; Wang ZB
Zhongguo Zhong Yao Za Zhi; 2023 Sep; 48(17):4702-4710. PubMed ID: 37802809
[TBL] [Abstract][Full Text] [Related]
14. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
15. [IL-12 induces autophagy via AKT/mTOR/STAT3 signaling pathway in human hepatoma cells].
Liu C; Xie C; Lin Y; Wu B; Wang Q; Li Z; Tu Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Jul; 32(7):870-5. PubMed ID: 27363263
[TBL] [Abstract][Full Text] [Related]
16. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
17. [Morin induces autophagy and apoptosis in hepatocellular carcinoma cells through Akt/mTOR/STAT3 pathway].
Zhao XY; Tian YY; Liu C; Li YL; Lyu YN; Yu SY; Tian SQ; Pei HL; Zuo ZP; Wang ZB
Zhongguo Zhong Yao Za Zhi; 2023 Aug; 48(16):4475-4482. PubMed ID: 37802874
[TBL] [Abstract][Full Text] [Related]
18. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
19. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
20. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]